Nuvation Bio Inc.
Here’s whether Nuvation Bio Inc. (NUVB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.69% over 10 days); strong 1-year return of +155.8%; 3-month momentum positive (+31.3%). Concerns: declining volume on rally — weak conviction (0.76x 30d avg). Currently 34.1% off its 52-week high. Score: +5/7.
NUVB is in a confirmed uptrend, trading above both its 50-day ($5.35) and 200-day ($5.63) moving averages. An RSI of 68.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +155.8% compares to +16.5% for SPY (beat the market by 139.3%). The current 34.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.